Regeneron Pharmaceuticals Inc

REGN trades at a remarkably modest 16.3 P/E for a biotech heavyweight with a $79.2B market cap, suggesting the market has priced in meaningful caution. The RSI of 36.6 signals oversold conditions, yet short interest remains minimal at 2.86% of float—indicating skepticism isn't fueled by crowded bearish bets. Trading below its 52-week high while in oversold territory creates an intriguing asymmetry: the stock has room to recover from depressed technical levels, though the discounted valuation suggests near-term catalysts may be lacking or uncertainty about pipeline execution persists. This setup implies either genuine value opportunity or that fundamental headwinds justify the conservative multiple